World’s first malaria vaccine soon

About 95 percent of the Indian population resides in malaria-endemic areas

shreerupa

Shreerupa Mitra-Jha | November 19, 2016 | Geneva


#Africa   #India   #WHO   #vaccine   #Malaria  


 The world’s first malaria vaccine will be rolled out in pilot settings in 2018, the results of which would give an indication of whether they can be deployed on a wider scale, the World Health Organisation confirmed on Friday. 

 
The first-generation vaccine known as RTS, S will be tried in pilot projects in sub-Saharan Africa in 2018. Also known as Mosquirix, it works against P. falciparum, the most deadly malaria parasite globally, and has been in development for the past three decades. Until now, vaccines fought viruses and bacteria but this is the first vaccine of its kind to fight parasites targeting the T-cells, which are part of the body’s immune system. 
 
“The pilot deployment of this first-generation vaccine marks a milestone in the fight against malaria,” said Dr. Pedro Alonso, Director of the WHO Global Malaria Programme, said in a statement. 
 
WHO estimates that India takes the disproportionate burden for the vector-borne disease accounting for 75 percent of all malaria cases in South-East Asia. About 95 percent of the Indian population resides in malaria-endemic areas. However, 80 percent of the disease is concentrated in areas where 20 percent of the population resides in tribal and hard-to-reach or inaccessible areas—typically rural areas of eastern and north-eastern states. 
 
Three of the world’s biggest health financing institutions—Gavi: the Vaccine Alliance, the Global Fund to Fight AIDS, Tuberculosis and Malaria and UNITAID—came together to tackle a disease that killed 4,38,000 people, largely children, in 2015. 
 
While the Global Fund yesterday approved $15 million for the malaria vaccine pilots, Gavi and UNITAID had earlier in the year announced commitments of up to $27.5 million and $9.6 million, respectively, for the first four years of the vaccine programme. 
 
RTS,S that has been developed by British drugmaker GlaxoSmithKline is, however, only partially effective and will only be deployed on a pilot basis before a call on its wide-scale use is taken. 
 
It is the only vaccine to have successfully completed the important Phase 3 clinical trials, involving 15,000 infants and young children in seven countries in sub-Saharan Africa. 
 
However, with the older children (between five and 17 months of age) who participated in the clinical trials, there was a risk of febrile seizures within a week after any one of the four doses of the vaccine while with infants, these seizures were apparent only after the fourth dose. WHO says that there were “no long-lasting consequences due to any of the febrile seizures”.
 
Also, during the Phase 3 RTS,S trials, meningitis and cerebral malaria cases increased among the older children who received the malaria vaccine as compared to the control group. However, no such increase was observed in infants aged 6–12 weeks. The significance of these findings in relation to the vaccination is unclear, the UN’s health agency says. 
 
 Mosquirix, created as a partnership between GSK and the PATH Malaria Vaccine Initiative (MVI), needed an investment of more than $565 million of which Bill and Melinda Gates Foundation have contributed more than $200 million while African research centres contributed the rest.
 
The vaccine was approved by the European Medicines Agency in July last year paving the way for WHO to adopt the SAGE-MPAC recommendations at the beginning of the year of a pilot implementation of the RTS,S vaccine in three to five settings in sub-Saharan Africa. 
 
“These pilots are critical to determine whether this vaccine can be rolled out more broadly, adding an important new tool to the proven interventions we already have in the fight against malaria,” Dr Seth Berkley, CEO of Gavi, the Vaccine Alliance said. 
 
 

Comments

 

Other News

Reform first, privatise later: Bibek Debroy to railways

Before privatisation and corporatisation, the Indian Railways need to undertake major reforms including commercial accounting, decentralisation and human resource among others, said Bibek Debroy, economist and member, NITI Aayog at Railways Reforms and Governance Conclave organised by Governance Now on Fri

NTPC plans for 32 GW installed capacity via renewable sources

NTPC Ltd has raised Rs 2,000 crore through green masala bonds in overseas market under its $4 billion medium term note programme, union minister Piyush Goyal informed the Lok Sabha. The proceeds of these bonds will be used for financing renewable energy projects in accordance with applicable

Big test for Palanisami

It’s been over a month since the power centre in Tamil Nadu shifted from Poes Garden to Greenways Road in Chennai. The thirteenth chief minister of the state, Edappadi K Palanisami, is taking baby steps to bring about a change in the state which has been battling political uncertainty for the past fe

A trowelful of empowerment

When her husband died last year, 60-year-old Chakkamma was not sure whether she would be able to have some money of her own: she has a son who looks after her, but she wanted to maintain a degree of independence. Opportunity came knocking when the Tamil Nadu government, as part of its Pudhu Vaazhvu (or new

Should Shiv Sena MP Ravindra Gaikwad be arrested for assaulting an Air India employee?

Should Shiv Sena MP Ravindra Gaikwad be arrested for assaulting an Air India employee?

Railways suffered over Rs 33,000 crore loss on passenger service: CAG

  The Railways was unable to meet its operational cost of passenger and other coaching services. During 2014-15, there was a loss of Rs 33,821.70 crore on passenger and other coaching services. The freight services earned a profit of Rs 38,312.59 crore which indicated that 88.28 percent

Video

जानिए क्यों ये किसान अर्धनग्न अवस्था में बैठे हैं जंतर मंतर पर

Current Issue

Opinion

Facebook    Twitter    Google Plus    Linkedin    Subscribe Newsletter

Twitter